Multicentric, Randomized, Open-label Trial to Evaluate the Superiority of Fixed Dose Combination of Oxomemazine, Guaifenesin and Potassium Iodate to Guaifenesin Monotherapy in Acute Cough Treatment

The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.

Start Date01 Oct 2012

Sponsor / Collaborator

EMS SA (Brazil)

100 Clinical Results associated with Oxomemazine

100 Translational Medicine associated with Oxomemazine

100 Patents (Medical) associated with Oxomemazine

Literatures (Medical) associated with Oxomemazine

01 Oct 2024·European Journal of Clinical Pharmacology

No evidence of clinical efficacy of oxomemazine in cough, according to a systematic review

Review

Author: Blanchard, Clara ; Dubois, Estelle ; Bacon, Trystan ; Boussageon, Rémy ; Vaillant-Roussel, Hélène

PURPOSECough is a prevalent symptom driving patients to seek medical attention in general practice. Despite its widespread use, the clinical efficacy of oxomemazine, the second most reimbursed molecule in France for symptomatic cough treatment, remains uncertain. This study aims to systematically evaluate the clinical efficacy of oxomemazine in cough.METHODSA systematic literature review with meta-analysis of randomized controlled trials (RCTs) was conducted according to the Rebuild the Evidence Base (REB) protocol. Clinical trials comparing the efficacy of oxomemazine versus placebo or active comparator in cough were searched for. Trials with insufficient data were excluded. Searches were conducted across major databases (Medline, Cochrane Central Register of Controlled Trials, and Embase) and trial registries (World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov). RCTs comparing oxomemazine versus placebo or active comparators in cough were sought. Risk of bias was assessed using the Cochrane Collaboration's RoB2 tool. The protocol was preregistered on PROSPERO under the number CRD42022345496 (15). This study received no funding.RESULTSNo RCTs were at low risk of bias. Therefore, no meta-analysis was conducted, in accordance to the pre-specified protocol.CONCLUSIONSThis systematic review highlights the lack of evidence regarding the efficacy of oxomemazine in cough treatment and underscores the need for further well-designed clinical trials to inform its clinical utility in primary care settings.

01 Apr 2022·BioanalysisQ4 · MEDICINE

Enantiomeric Separation of Oxomemazine in Rabbit Plasma by Ultra-Fast LC and Application in a Stereoselective Pharmacokinetic Study

Q4 · MEDICINE

Article

Author: Gurupadayya, Bannimath ; Koganti, Sairam ; Raikar, Prachi ; Mounika, Peddaguravagari ; Rajan, Surulivel

Aim: Ultra-fast LC was used to establish a new bioanalytical method for enantiomeric separation of oxomemazine. Methods: The proposed study was carried out using the ultra-fast LC technique with an amylose chiral column. The bioanalytical approach was used in rabbit plasma following US FDA regulations and then extended to oxomemazine enantiomeric separation using metronidazole as the internal standard. Results: The retention times of ( R)-oxomemazine, ( S)-oxomemazine and the internal standard were found to be 9.511, 10.712 and 6.503 min, respectively. Within-run and between-run precision (percent relative standard deviation) was found to be in the range of 0.018–0.102% for ( R)-oxomemazine and 0.028–0.675% for ( S)-oxomemazine, whereas accuracy (%) was found to be in the range of 95.971–99.720% for ( R)-oxomemazine and 97.199–103.921% for ( S)-oxomemazine. Conclusion: The findings revealed that stereospecific distribution of oxomemazine enantiomers does not change significantly.

01 Dec 2018·Saudi Pharmaceutical JournalQ3 · MEDICINE

Green chromatographic method for analysis of some anti-cough drugs and their toxic impurities with comparison to conventional methods

Q3 · MEDICINE

ArticleOA

Author: Abdelaleem, Eglal A ; Abdelwahab, Nada S

Toxic solvents are widely used in chemical laboratories, which are dangerous on health, safety of workers, and environment. Green chemistry established different principles to keep safety of environment, one of these goals is to replace toxic solvents by greener alternatives or by minimizing the used volumes. Paracetamol (PAR), Guaifenesin (GUF), Oxomemazine (OX), and Sodium benzoate (SB) combination is a widely used cough preparation. 4- aminophenol (4-AP) is PAR poisonous impurity and related substance. Guiacol (GUC) is GUF impurity and related substance; its presence may lead to rejection of GUF sample. An eco-friendly HPTLC method was developed to quantify the studied drugs and their impurities. Chromatographic separation was achieved on HPTLC 60F254 plates using ethylacetate: methanol: 0.05 M ammonium chloride buffer (100: 2: 5, by volume) as a mobile phase and scanning at 225 nm. The linear ranges were 0.25-3.50, 0.50-8.00, 0.25-4.00, 0.20-8.00, 0.05-4.00, and 0.25-4.00 µg/band for PAR, GUF, OX and SB, 4-AP, and GUC. Method was successfully applied to available syrup and suppositories. It compared well with the reported method. It can be considered as an alternative green method for previously developed TLC method. Greenness profile of the method proved that it is greener than the reported methods being time and solvents saving.

100 Deals associated with Oxomemazine

External Link

KEGG	Wiki	ATC	Drug Bank
D07401	Oxomemazine	R06AD08	DB13820

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypersensitivity	-	-	-
Pruritus	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis